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Background: In recent years the physiological and pathological importance of fatty acids in both the periphery
and central nervous system (CNS) has become increasingly apparent. However surprisingly limited research has
been conducted comparing the fatty acid composition of central and peripheral lipid stores.
Methods: The present study compared the distribution of polyunsaturated (PUFA), as well as specific saturated
(SFA) and monounsaturated (MUFA) fatty acids in the whole blood and cerebrospinal fluid (CSF) of humans. Gas
chromatography with flame ionization detection was used to determine the fatty acid profiles of twenty-eight
matched CSF and whole blood samples. Multiple linear regression modeling, controlling for age, was used to
identify significant relationships.
Results: A significant positive relationship was seen between whole blood total omega-3 fatty acids and the CSF
omega-3 subfractions, docosapentaenoic acid (DPA) (P = 0.019) and docosahexaenoic acid (DHA) (P = 0.015). A direct
association was also observed between the whole blood and CSF omega-6 PUFA, arachidonic acid (AA) (P = 0.045).
Interestingly an inverse association between central and peripheral oleic acid was also found (P = 0.045).
Conclusions: These findings indicate a relationship between central and peripheral fatty acids of varying degrees of
unsaturation and chain length and support the view that some systemic fatty acids are likely to cross the human blood
brain barrier (BBB) and thereby influence central fatty acid concentrations.
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Nutritional supply of essential fatty acids is considered im-
portant for numerous physiological functions at every stage
of human life. At sufficient levels of incorporation, fatty
acids influence a number of cellular functions including
cell membrane fluidity [1], membrane protein-mediated re-
sponses [2], eicosanoid generation [3], gene expression [4],
and cell signaling [5]. Through these mechanisms, fatty
acids influence cell and tissue physiology, and the way cells
and tissues respond to external signals in both the periph-
ery and CNS.
The unique lipid profile of the CNS has been recog-
nized for a number of decades. Of all organs in the human* Correspondence: rossg@sah.org.au
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reproduction in any medium, provided the orbody, excluding adipose tissue, the nervous system has the
highest lipid content. The dry weight of an adult brain is
approximately fifty-five percent lipid, thirty-five per-
cent of which is accounted for by PUFA’s. Of these,
docosahexaenoic acid (DHA; C22:6n-3) and arachidonic
acid (AA; C20:4n-6), respectively, are present in the highest
concentrations [6]. In comparison alpha-linolenic acid
(ALA; C18:3n-3), eicosapentaenoic acid (EPA; C20:5n-3),
and docosapentaenoic acid (DPA; 22:5n-3) comprise only
one percent of total brain fatty acids [7]. Since these early
observations many functions of brain PUFA’s, including
their role in neurogenesis, cell survival, signal transduction,
and neuroinflammation have been identified [8-11]. Fur-
thermore alterations in brain PUFA metabolism have been
linked to various neurological disorders including major
depression and Alzheimer’s disease [12,13].
A comparatively small body of research has focused
on the function of other fatty acid species within thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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both SFA and their derivatives are required for brain
health. In a recent study using human frontal cortex tissue
Martín et al. demonstrated that lipid rafts, membrane
structures intimately associated with cell signalling, are
predominately composed of the SFA’s palmitic (C16:0) and
stearic (C18:0) acid [14]. Oleic acid (C18:1n-9), formed
from the desaturation of stearic acid, has been shown to
promote axonogenesis in the striatum during brain devel-
opment [15], and is used as a cerebral energy source when
glucose availability diminishes [16].
Even though the important role of fatty acids within
the periphery and CNS has been firmly established, the
mechanisms by which fatty acids enter the brain are still
not fully understood. The brain is protected by the BBB
that forms a cellular interface between the blood and the
brains extracellular matrix. In order to enter the brain,
fatty acids must move across both luminal and abluminal
membranes of the BBB endothelial cells, and then cross
the plasma membrane of neural cells. It is currently
thought that fatty acids cross the BBB via either specificTable 1 Comparison between whole blood and cerebrospinal
Fatty acid Whole
C:Dn-x Common name Mean (±SE)
C16:0 palmitic acid 23.37 (0.43)
C16:1n-7 palmitoleic acid 2.56 (0.15)
C18:0 stearic acid 8.68 (0.28)
C18:1n-7 vaccenic acid 2.22 (0.08)
C18:1n-9 oleic acidc 21.21 (0.50)
C18:2n-6 linoleic acid 20.40 (0.53)
C18:3n-3 alpha-linolenic acid 0.74 (0.04)
C18:3n-6 gamma-linolenic acid 1.52 (0.06)
C20:0 arachidic acid 0.26 (0.02)
C20:1n-9 eicosenoic acid 0.24 (0.01)
C20:2n-6 eicosadienoic acid 1.17 (0.08)
C20:3n-6 dihomo-gamma-linolenic acid 1.73 (0.05)
C20:4n-6 arachidonic acidb 8.00 (0.38)
C20:5n-3 eicosapentaenoic acid 2.01 (0.15)
C22:5n-3 docosapentaenoic acidc 1.98 (0.10)
C22:6n-3 docosahexaenoic acidc 3.91 (0.17)
Total SFA 32.31 (0.28)
Total MUFAb 26.26 (0.57)
Total omega-3 PUFAc 8.64 (0.33)
Total omega-6 PUFA 32.80 (0.53)
Ratio omega-6:omega-3 3.92 (0.13)
Fatty acids are expressed as a percentage of total fatty acids.
an = 28, bP < 0.05 for comparison between respective whole blood and CSF fatty ac
cP < 0.05 for comparison between whole blood total omega-3 PUFA and CSF DPA (C
ND not detected.fatty acid transporter proteins, passive diffusion using a
‘flip flop’ mechanism or a combination of both [17-19].
While the physiological and pathological importance of
fatty acids in both the periphery and CNS has become in-
creasingly apparent, surprisingly limited research has been
conducted comparing the fatty acid composition of the
CNS with blood, still fewer studies have been conducted
in humans. Does the content of fatty acids in human
blood reflect the CNS lipid profile, and if so, to what ex-
tent? As the development of some neurodegenerative dis-
orders have been linked to alterations in both brain and
red blood cell fatty acid proportions [12,13], and because
rodents are not always reliable as preclinical models for
human disease, the present study sought to determine the
distribution of PUFA’s, as well as specific SFA and MUFA,
in matched human whole blood and CSF samples.
Results
The distribution of various fatty acids in the CSF and
whole blood are presented in Table 1, expressed as a
percentage of total fatty acids.fluid fatty acids levels
blooda (%) CSFa (%)
Min Max Mean (±SE) Min Max
18.77 27.68 27.88 (0.76) 14.77 55.55
0.75 4.43 2.71 (0.18) 0.89 7.24
6.59 11.55 18.70 (0.78) 9.79 41.11
1.48 3.31 3.76 (0.17) 0.00 7.61
15.8 26.17 25.48 (0.61) 11.74 33.94
13.33 26.04 7.01 (0.33) 2.87 17.47
0.46 1.42 2.54 (0.26) 0.59 16.14
0.98 2.06 ND - -
0.12 0.51 ND - -
0.17 0.37 1.21 (0.14) 0.00 6.14
0.30 2.01 ND - -
1.07 2.31 1.02 (0.12) 0.00 4.84
4.78 12.47 3.47 (0.20) 0.99 9.00
1.04 3.87 1.87 (0.28) 0.00 10.66
1.06 3.17 2.94 (0.18) 0.84 8.46
2.54 5.92 1.41 (0.12) 0.00 5.70
29.06 35.20 46.58 (1.27) 24.57 75.94
18.92 31.71 33.16 (0.69) 14.55 41.21
6.05 12.66 8.76 (0.55) 2.65 28.52
25.63 38.79 11.50 (0.49) 4.85 23.53
2.73 5.54 1.47 (0.07) 0.41 3.45
id concentrations using multiple linear regression.
22:5n-3) and DHA (C22:6n-3) using multiple linear regression.
Figure 1 Relationship between peripheral and central PUFA.
(A) A significant positive association was observed between whole
blood total omega-3 and the CSF omega 3 subfraction DPA (P = 0.019,
n = 28). (B) Likewise a significant positive association was observed
between whole blood total omega-3 and the CSF omega 3 subfraction
DHA (P = 0.015, n = 28). (C) A positive association was observed
between whole blood and CSF AA (P = 0.045, n = 28). Comparisons
were made using multiple linear regression controlling for age.
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No association was observed for individual omega-3 PUFA
(ALA or EPA or DPA or DHA) between whole blood and
CSF. However a significant positive relationship was seen
between whole blood total omega-3 fatty acids and the
CSF omega-3 subfractions i.e. DPA (C22:5n-3) (P = 0.019,
n = 28) and DHA (C22:6n-3) (P = 0.015, n = 28) (Figure 1).
A one unit increase in whole blood total omega-3 fatty acid
was associated with a 0.275 unit increase in CSF DPA.
Similarly a one unit increase in whole blood total omega-3
fatty acid inferred a 0.143 unit increase in CSF DHA.
A positive relationship was also observed between the
whole blood and CSF omega-6 PUFA AA (C20:4n-6)
(P = 0.045, n = 28) (Figure 1). A one unit increase in whole
blood AA was associated with a 0.865 unit increase in CSF
AA. No associations were observed for other omega-6
PUFA.
CSF and whole blood MUFA’s
In this cohort a significant inverse relationship was ob-
served between whole blood and CSF oleic acid (C18:1n-9)
(P = 0.026, n = 28) (Figure 2). A one unit increase in whole
blood oleic acid was associated with a 0.836 unit decrease
in CSF oleic acid. Consistent with this, a significant inverse
relationship was also detected between whole blood and
CSF total MUFA (P = 0.013, n = 28). No associations were
observed for other individual MUFA species.
In order to explain the unexpected inverse relationship
observed between whole blood and CSF oleic acid, the
data was further analyzed to determine if there was an
association between whole blood oleic and the CSF ste-
aric: oleic acid ratio, a putative index of Δ9-desaturase ac-
tivity. As predicted, due to the ability of oleic acid to
inhibit Δ9-desaturase, a one unit increase in whole blood
oleic acid was associated with a 0.141 unit decrease in
the CSF stearic: oleic acid ratio (P = 0.002, n = 28). Cor-
respondingly a one unit increase in whole blood oleic
acid was associated with a 1.587 unit increase in CSF ste-
aric acid (P = 0.004, n = 28) and a one unit increase in
CSF stearic acid was associated with a 0.466 unit de-
crease in CSF oleic acid (P = 0.000, n = 28) (Figure 2).
CSF and whole blood SFA’s
No associations were observed between whole blood and
CSF SFA species.
Discussion
While a significant body of work has focused on the func-
tion of fatty acids in both the periphery and CNS, limited
research has been conducted on the compartmentalization
of fatty acids between blood and cerebrospinal fluid. To
our knowledge this is the first study to compare the distri-
bution of PUFA, as well as specific SFA and MUFA, in the
whole blood and CSF of humans. In this cohort we found
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ciated with the CSF omega-3 PUFA’s, DPA and DHA. This
is consistent with a recent report by Jumpertz et al. who
also observed an association between plasma and CSF
ALA and DHA [20]. This data is also consistent with stud-
ies in rats showing diets enriched with omega 3 improved
brain DHA levels [21]. A positive relationship between the
whole blood and CSF omega-6 subfraction AA was also
found. While Jumpertz et al. did not observe an associ-
ation between plasma and CSF omega-6 PUFA’s [20],
others have demonstrated that peripherally injected [11C]-
arachidonic acid can be visualized, after only 15 minutes,
in human cranial images [22]. Taken together, this data
suggests that in healthy humans PUFA’s can cross the
BBB at physiological concentrations. In apparent con-
trast, Carver et al. reported an inverse association be-
tween postmortem human erythrocyte and brain tissue
DHA and AA levels [23]. Similarly in schizophrenic pa-
tients an inverse association between erythrocyte and
CSF DHA levels has been reported [24]. The reasons for
these observed inverse associations are unknown, how-
ever, it is noted that the specimens used in these studies
were either postmortem tissue or from participants with
documented neurological abnormalities suggesting the
potential for unexpected bias due to either sample quality
or clinical condition.
Several models regarding the uptake of fatty acids by
the brain have been proposed and recently reviewed by
Chen et al. [25]. Current evidence appears to support
both transport protein facilitated movement and passive
diffusion of fatty acids across the BBB. In 2009 Ouellet
et al. demonstrated, using an in situ brain perfusion tech-
nique in mice, that radiolabeled DHA and eicosapenta-
enoic acid (EPA; C20:5n-3) readily cross the BBB. As the
brain uptake of [14C]-DHA and [14C]-EPA was not satur-
able, Ouellet et al. postulated that these compounds
enter the brain by passive diffusion [26]. However the
presence of several BBB lipid transporter proteins sug-
gests that some fatty acids, at least in part, are facilitated
into the CNS. Recently Mitchell et al. investigated fatty
acid transport across an in vitro BBB model. These re-
searchers demonstrated that fatty acid transport protein
1 and 4 (FATP-1, FATP-4) are the predominant fatty acid
transport proteins expressed in the human BBB and that
they, in addition to fatty acid translocase/CD36, are in-
volved in fatty acid permeability. It was also observed
that the specific chemical structure of individual fatty
acids influences the rate of transport, with short to
medium chain SFA’s moving across the microvessel
monolayer more readily than longer chained SFA’s, whilst
unsaturated fatty acids accumulated in the basolateral
medium to a higher degree than SFA of similar chain
length [27]. If the movement of fatty acids across the
BBB is indeed facilitated then the selective uptake of fattyacids by lipid transporter proteins could potentially alter
the equilibrium between blood and central lipid pools
and may explain the lack of association observed be-
tween some respective fatty acid species in this study.
Clearly further research into the mechanism of fatty acid
transport across the BBB is required.
While it is generally accepted that the brain must ob-
tain essential fatty acids from the blood, evidence sug-
gests that it is also capable of independently synthesizing
a variety of lipids [28]. Fatty acids are formed by pro-
cesses involving the reductive polymerization of acetyl-
CoA in which the hydrolysis of ATP provides the energy
required for carbon–carbon bond formation. Two main
pathways of fatty acid biosynthesis have been described.
The first pathway involves the de novo synthesis of SFA’s
through the action of acetyl-CoA carboxylase and fatty
acid synthase. The second pathway involves the desatur-
ation or elongation of these SFA’s by Δ9-desaturase
resulting in the formation of (n-5), (n-7) and (n-9) MUFA.
The desaturation and elongation of the essential fatty acids,
linoleic acid (LA) and ALA, results in the formation of the
(n-6) and (n-3) family of PUFA’s respectively [29]. The syn-
thesis of fatty acids is determined by both the cellular de-
mand for fatty acid species, allosteric effectors and the
variable availability of substrates. Regulation is often coor-
dinated at both the transcriptional and post-translational
level and is influenced by a plethora of factors including
circadian rhythms and various nutritional and hormonal
stimuli [30,31]. The likely differences in the fatty acid re-
quirement of cells in the periphery compared to those in
the CNS combined with the possible variable effects of
regulatory mechanisms may explain both the lack of, and
unexpected inverse association between some respective
fatty acid species in this study.
The MUFA oleic acid (C18:1n-9), formed from the de-
saturation of stearic acid (C18:0) through the activity of
Δ9-desaturase, is the primary fatty acid in the white mat-
ter of the mammalian brain [32]. In this study an inverse
relationship between CSF and whole blood oleic acid
was observed. This is consistent with a report by Carver
et al. who also observed an inverse association between
erythrocyte and brain tissue oleic acid in humans [23].
Importantly oleic acid prevents the de novo synthesis of
fatty acids by inhibiting the activity of both acetyl CoA
carboxylase and Δ9-desaturase [33,34]. Consistent with
this action, in this study we found that an increase in whole
blood oleic acid was associated with a decrease in the
stearic: oleic acid ratio, a putative index of Δ9-desaturase
activity. Oleic acid has also been shown to promote fatty
acid β-oxidation by reducing malonyl-CoA inhibition of
carnitine palmitoyltransferase-1(CPT1) and by increasing
the expression of genes linked to β-oxidation by a SIRT1/
PGC1α dependent mechanism [35-38]. Though supporting
data for the modulatory effect of oleic acid in the CNS
Figure 2 Relationship between peripheral and central SFA and MUFA. (A) A significant inverse association was observed between whole
blood and CSF oleic acid (P = 0.026, n = 28). (B) A significant inverse association was observed between whole blood oleic acid and the CSF
stearic: oleic acid ratio (P = 0.002, n = 28) (C) A significant positive association was observed between whole blood oleic and CSF stearic acid
(P = 0.004, n = 28). (D) A significant inverse association was observed between CSF stearic and oleic acid (P = 0.000, n = 28). Comparisons were
made using multiple linear regression controlling for age.
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explain the observed inverse association between whole
blood and CSF oleic acid (Figure 3).
In some contrast to our findings, Bourre and Dumont,
using rat feeding studies, observed that CNS tissue oleic
acid remained constant regardless of dietary intake [39].
The differences in these observations, between rats and
humans, may represent species differences for the cap-
acity of local oleic acid production within the CNS.
Conclusions
To our knowledge this is the first study to provide compara-
tive data on the distribution of fatty acids between the whole
blood and CSF of healthy humans. The data presented show
a relationship between central and peripheral fatty acids ofvarious degrees of unsaturation and chain length. Evidence
that both omega-3 and omega-6 PUFA cross the human
BBB at physiological concentrations is provided. As alter-
ation in brain fatty acid proportions has been linked to
some neurological disorders, these results provide a pre-
liminary reference point from which deviation from the
normal may be gauged. To further elucidate the role of
fatty acids in the pathophysiology of neurodegenerative
disorders, research into the fatty acid distribution between
not only blood and CSF but also brain tissue is required in
humans.
One limiting factor of our study is the modest number
of matched whole blood and CSF samples. However
these samples (CSF with matched blood) do represent
essentially healthy individuals with no apparent signs of
Figure 3 Interdependence of central stearic and oleic acids. Due to its unsaturated structure oleic acid (C18:1n-9) moves more readily than
stearic acid (C18:0) across the BBB. Within the CNS oleic acid can inhibit both Δ9-D and ACC resulting in decreased de novo synthesis of both itself and
steric acid. Simultaneously a decrease in melonyl CoA and it’s inhibition of CPT1 can promote an increase in central fatty acid β-oxidation. Oleic acid
also increases the expression of genes linked to fatty acid β-oxidation by a SIRT1/PGC1 dependent mechanism. (Abbreviations; ACC, acetyl CoA; FAS,
fatty acid synthase; ELO, elongase; Δ9-D, Δ9-desaturase; CPT1, carnitine palmitoyltransferase-1; cAMP/PKA, cyclic adenosine monophosphate/protein
kinase A; pSIRT1, phosphorylated sirtuin 1; PGC1α peroxisome proliferator-activated receptor gamma co-activator).
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were from older participants and that ageing results in a
number of metabolic changes that could potentially in-
fluence fatty acid synthesis and oxidation. Nevertheless,
the associations in this analysis were robust to the conser-
vative Bonferonni correction for multiple comparisons and




Male (n = 4) and female (n = 24) participants, who re-
quired a spinal tap for the administration of anesthetic
as part of routine care, were recruited at Sydney Advent-
ist Hospital, Australia. The average age of participants
was 49 years (SE = 3.6, interquartile range = 34). Partici-
pants were excluded from the cohort if they had a con-
firmed diagnosis of a neurological/neurodegenerative
disorder or CNS viral infection. In total 28 CSF and
matched blood samples were collected from consenting
participants considered in general good health.
Written informed consent was obtained from all par-
ticipants prior to commencement. Ethical approval wasobtained from the Human Research Ethics Committee,
Sydney Adventist Hospital.
Biochemical analysis
Fasting (≥10 h) blood and CSF samples were collected
by an accredited anesthetist no longer than 30 minutes
apart. CSF samples were collected, prior to injection of
spinal anesthetics, via standard lumber puncture. Blood
samples were collected into heparinized tubes from an
intravenous cannula inserted into a superficial vein on
an upper limb, prior to the administration of fluids or
anesthetics. CSF samples were prepared by centrifuging
at 1800 rpm for 10 minutes. All samples were stored in
butylated hydroxyl toluene coated tubes, within 1 hour
of collection, at −194 degrees Celsius until analysis.
The fatty acid composition of whole blood and CSF
lipids was determined according to a modification in the
method of Lepage and Roy [40], using an acetyl chloride
methylation procedure. Briefly 2 ml of methanol:toluene
(4:1 v/v) containing C19:0 (4 μg/ml) internal standard
was added to 200 μl of whole blood and 500 μl of CSF.
The fatty acids were then methylated by adding 200 μl of
acetyl chloride and heated at 100 degrees Celsius for 1 hour.
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K2CO3 solution. The samples were centrifuged at 3000 x g
for 10 minutes and the supernatant containing the fatty
acid methyl esters was transferred into glass vials.
Fatty acid methyl esters were quantified using a Hewlett
Packard 6890 Gas Chromatograph equipped with a flame
ionization detector. The identity of each fatty acid peak in
the sample was determined by comparing the peaks reten-
tion time with the retention time of synthetic standards of
known fatty acid composition. Fatty acid results are
reported as percentage of total fatty acids.
Statistical analysis
Statistical analyses were performed using SPSS version
16.0 for Windows. Data in Table 1 is presented as means
± standard error. The minimum and maximum observed
value is also shown. Multiple linear regression, control-
ling for age, was used to identify significant relationships
between whole blood and CSF fatty acids. Levene’s Test
of Equality was used to check homogeneity of variances
between groups while both the Kolmogorov-Smirnov,
Shapiro-Wilk and histogram analysis was used to check
normality of the variables. If the variances of the groups
were found to be either not homogenous and/or normality
tests for the variables were significant then further investi-
gation with graphical displays was performed to assess the
distributions of the variables. Adjusted P-values are pro-
vided throughout with test significance set at P-value < 0.05
after Bonferroni correction.
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